Loading…
PTC Therapeutics, Inc. is projected to rise to $93.21 by 2027, a +23% move from its current price of $75.52. PTCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $74.12 | $75.55 | $77.00 | +0.04% |
| Aug 2 | $73.57 | $75.58 | $77.64 | +0.07% |
| Aug 3 | $73.15 | $75.60 | $78.14 | +0.11% |
| Aug 4 | $72.81 | $75.63 | $78.56 | +0.15% |
| Aug 5 | $72.51 | $75.66 | $78.95 | +0.19% |
| Aug 6 | $72.24 | $75.69 | $79.30 | +0.22% |
| Aug 7 | $72.00 | $75.72 | $79.62 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $72.00 | $75.72 | $79.62 | +0.26% |
| Week 2 | $70.70 | $75.91 | $81.51 | +0.52% |
| Week 3 | $69.76 | $76.11 | $83.04 | +0.78% |
| Week 4 | $69.00 | $76.31 | $84.39 | +1.04% |
| Week 5 | $68.37 | $76.51 | $85.62 | +1.31% |
| Week 6 | $67.81 | $76.71 | $86.77 | +1.57% |
| Week 7 | $67.32 | $76.91 | $87.86 | +1.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia.
PTC Therapeutics, Inc. (PTCT) operates in the healthcare sector as a publicly traded company focused on treatments for rare disorders.
The current price is $78.52, with a market capitalization of $6.51B and a market rank of 1176.
The near-term price outlook is modestly constructive, and the longer-term forecast shows substantial upside, with the avg price rising through the forecast horizon to $145.23 by 2030 and to $1,065.65 by 2050, reflecting meaningful upside potential despite the uncertainties inherent in long-range predictions.
These figures illustrate a path of continued growth in the estimated prices across the horizon, though they are forecasts and not guarantees.
A major floor 14.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.4% away) — a key level to hold.
The nearest ceiling, 18.6% above — a clean break opens room to run.
A major ceiling 25.7% above — clearing it would confirm fresh momentum.
Key PTCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PTCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $75.60 | Sell | $75.80 | Sell |
| MA 10 | $77.00 | Sell | $77.00 | Sell |
| MA 20 | $80.38 | Sell | $78.31 | Sell |
| MA 50 | $77.19 | Sell | $77.29 | Sell |
| MA 100 | $72.95 | Buy | $74.86 | Buy |
| MA 200 | $73.11 | Buy | $70.78 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.84 | Neutral |
| Stoch RSI (14) | 26.86 | Neutral |
| CCI (20) | -81.90 | Neutral |
| Williams %R (14) | -84.94 | Info |
| MACD (12,26,9) | -0.92 | Sell |
| ROC (12) | -3.25 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 15.06 | Buy |
| TRIX (15) | 0.00 | Buy |
| Awesome (5,34) | -4.57 | Sell |
| Ultimate (7,14,28) | 23.36 | Buy |
| Momentum (10) | -3.00 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 74.34 | Buy |
| ADX (14) | 18.54 | Neutral |
| ATR (14) | 1.21 | Info |
The 30-day technical picture is bullish in sentiment, with RSI(14) at 50 and moving averages guiding near-term momentum. The SMA50 is $75.98 and the SMA200 is $72.44, providing short-term support and trend context. Key levels to watch are support at $68.68 and resistance at $89.55.
Over the next 30 days, the price range is cited as $66.86 to $92.21, indicating some near-term volatility around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.82 | $75.52 | $100.08 | 0% | Neutral | |
| $76.38 | $93.21 | $118.89 | +23% | Bullish | |
| $88.94 | $110.62 | $145.00 | +46% | Bullish | |
| $99.21 | $125.34 | $167.86 | +66% | Bullish | |
| $101.92 | $130.52 | $178.00 | +73% | Bullish | |
| $121.51 | $157.54 | $218.30 | +109% | Bullish | |
| $146.31 | $191.88 | $269.70 | +154% | Bullish | |
| $165.53 | $219.39 | $312.42 | +191% | Bullish | |
| $189.00 | $253.03 | $364.68 | +235% | Bullish | |
| $194.90 | $263.42 | $383.93 | +249% | Bullish | |
| $326.71 | $460.83 | $704.18 | +510% | Bullish | |
| $573.68 | $868.60 | $1,423.60 | +10.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $62.82 | $75.52 | $88.04 | +0.00% |
| August 2026 | $66.87 | $77.98 | $92.69 | +3.26% |
| September 2026 | $66.60 | $78.12 | $93.73 | +0.17% |
| October 2026 | $67.63 | $79.70 | $96.34 | +2.02% |
| November 2026 | $69.31 | $81.98 | $99.70 | +2.86% |
| December 2026 | $68.95 | $81.84 | $100.08 | -0.17% |
Click any year to see its month-by-month PTCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PTCT to range from $62.82 to $100.08 through 2026. The $75.52 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PTCT price prediction for 2027 points to an average of $93.21 (low $76.38, high $118.89) — a potential gain of +23% on today's $75.52. Buyers look set to stay in control over this stretch.
In 2028, PTCT is projected to trade between $88.94 and $145.00, averaging $110.62 — a potential gain of +46% from today's $75.52. That is up +19% on the projected 2027 average. Momentum favours further upside here.
PTC Therapeutics, Inc.'s 2029 outlook centres on $125.34, within a $99.21 to $167.86 range. That is up +13% on the projected 2028 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, PTCT could reach as high as $178.00, with a base case around $130.52 and support toward $101.92 — roughly +73% from $75.52. Momentum favours further upside here.
Expect PTCT to range from $121.51 to $218.30 through 2031. The $157.54 average target implies a +109% move from current prices. That is up +21% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The PTCT price prediction for 2032 points to an average of $191.88 (low $146.31, high $269.70) — a potential gain of +154% on today's $75.52. Momentum favours further upside here.
In 2033, PTCT is projected to trade between $165.53 and $312.42, averaging $219.39 — a potential gain of +191% from today's $75.52. That is up +14% on the projected 2032 average. Buyers look set to stay in control over this stretch.
PTC Therapeutics, Inc.'s 2034 outlook centres on $253.03, within a $189.00 to $364.68 range. That is up +15% on the projected 2033 average. That marks a +235% change versus current levels. Momentum favours further upside here.
By 2035, PTCT could reach as high as $383.93, with a base case around $263.42 and support toward $194.90 — roughly +249% from $75.52. Buyers look set to stay in control over this stretch.
Expect PTCT to range from $326.71 to $704.18 through 2040. The $460.83 average target implies a +510% move from current prices. That is up +75% on the projected 2035 average. Momentum favours further upside here.
The PTCT price prediction for 2050 points to an average of $868.60 (low $573.68, high $1,423.60) — a potential gain of +10.5x on today's $75.52. Buyers look set to stay in control over this stretch.
Investing $1,000 in PTCT today (≈ 13.241525 PTCT) could be worth
$11,501.64
+$10,501.64 (+1050%) by 2050 · US Dollar
Based on the average projected PTCT price of $868.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PTCTwould be worth at today's price.
$1,000 invested in PTCT on Jul 30, 2025 (≈ 19.630939 PTCT) would be worth
$1,482.53
+$482.53 (+48.3%) today · 1.48× · US Dollar
Based on a PTCT entry price of $50.94 vs. today's $75.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $78.45 | $962.65 | -3.7% |
| 1 month ago | $81.57 | $925.83 | -7.4% |
| 3 months ago | $65.15 | $1,159.17 | +15.9% |
| 6 months ago | $75.53 | $999.87 | -0.0% |
| 1 year ago | $50.94 | $1,482.53 | +48.3% |
| All time (5.0y) ago | $38.68 | $1,952.43 | +95.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PTCT forecast.
Our base-case forecast reaches $150.00 around 2031.
Implied market cap at $150.00: $12.44B
The multi-year forecast shows a bullish tilt after 2026, with 2026 at min $62.82, avg $78.52, max $105.98 and ROI 0 (sentiment NEUTRAL). By 2030, the avg is $145.23 with a min of $109.68, a max of $206.57, and ROI 85, with sentiment BULLISH.
In 2040, the avg is $568.46 with a min of $377.05, a max of $928.00, and ROI 624, with sentiment BULLISH. In 2050, the avg is $1,065.65 with a min of $640.62, a max of $1,891.01, and ROI 1257.2, with sentiment BULLISH.
Overall, the forecast points to substantial upside in the long run, but these are estimates and not guarantees. The trajectory indicates stronger upside beyond 2030, particularly by 2040 and 2050, against a backdrop of early neutral signals in 2026.
Tap a question to reveal the answer.
In 2030, the avg is $145.23, with a min of $109.68 and a max of $206.57, and ROI 85; sentiment BULLISH.
The forecast shows a neutral stance in 2026 and a bullish trend from 2027 onward, with increasing averages and ROIs through 2030 and into 2040 and 2050. Key milestones include 2030 avg $145.23 and ROI 85, 2040 avg $568.46 and ROI 624, and 2050 avg $1,065.65 and ROI 1257.2, but these are estimates and not guarantees.
The 2030 max in the forecast is $206.57, which exceeds $200.
The current price is $78.52 and the market cap is $6.51B; the stock ranks 1176.
The 30-day range is from a low of $66.86 to a high of $92.21.
PTC Therapeutics, Inc. Community Discussion
0Share your PTC Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.